December 6th 2021
The importance of multidisciplinary care in chronic lymphocytic leukemia and proper patient education on adverse events associated with novel targeted therapies.
Common toxicities associated with novel targeted therapies, such as BTK inhibitors, used to treat chronic lymphocytic leukemia, and recommendations on how to manage with dose adjustments.
Recommendations for using novel targeted therapies to treat chronic lymphocytic leukemia in the frontline setting.
Oncology hematology health care professionals from Memorial Sloan Kettering Cancer Center discuss how to manage a 67-year-old woman with chronic lymphocytic leukemia who develops progressive fatigue and night sweats.
Staging criteria used in the diagnosis of chronic lymphocytic leukemia, and recommendations for talking with patients about molecular testing results and goals of therapy.
An overview of tests used to evaluate patients for chronic lymphocytic leukemia and, consequently, inform treatment decisions.
Oncology hematology health care professionals from Memorial Sloan Kettering Cancer Center react to the variation in symptoms that patients suspicious of chronic lymphocytic leukemia present with.
December 1st 2021
Treatment algorithms used in clinical practice by breast oncologists to best approach and subsequently treat patients with HER2-positive metastatic breast cancer.
A panel of breast oncologists highlight their therapy preferences for a woman with HER2-positive metastatic breast cancer previously treated with docetaxel-trastuzumab-pertuzumab followed by paclitaxel and cisplatin.
August 28th 2020
Leora Horn, MD, MSc, FRCPC, discusses the role of mobocertinib in patients with non–small cell lung cancer.
October 29th 2013
Newest OncLive partner is a renowned translational cancer center that is at the forefront of comprehensive cancer treatment and research into advanced targeted therapies.
September 25th 2013
World-class cancer research and treatment center is the latest to partner with OncLive to promote its research, events, and initiatives
July 29th 2011
Amid growing cost pressures in the pharmaceutical industry, many small companies are playing an increasingly active role in drug development.
July 26th 2011
Srdan Verstovsek, MD, PhD, is a medical oncologist and associate professor in the Department of Leukemia at the University of Texas MD Anderson Cancer Center in Houston.
July 25th 2011
Ruxolitinib, an investigational JAK inhibitor, demonstrated significant benefits for patients with myelofibrosis.
June 27th 2011
Martine Piccart-Gebhart, MD, PhD is a professor of oncology at the Universite Libre de Bruxelles and director of the Medicine department at the Jules Bordet Institute in Brussels, Belgium.
June 23rd 2011
FDA digest from June discussing warning labels, pancreatic treatment choices, and the quest for a lymphoma drug.
Internationally known experts will discuss the latest research in breast and lung cancers at 2 conferences that the Physicians' Education Resource (PER) is hosting in California in August.
June 13th 2011
Breast cancer resources gathered from across the web including a news brief, patient education, clinical trials and CME/CE
June 8th 2011
Hematologic cancer resources gathered from across the web including a news brief, patient education, clinical trials and CME/CE